ANGPTL2 and acute myeloid leukemia: Endothelial cells themselves, with the release of angiopoietin-like 2 (ANGPTL2)-containing EVs, are able to accelerate AML progression through the interaction between ANGPTL2 and leukocyte immunoglobulin-like receptor B2 (52).